Get started
AKERO THERAPEUTICS INCAKERO THERAPEUTICS INCAKERO THERAPEUTICS INC

AKERO THERAPEUTICS INC

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Forecast

1AKRO chart


Full chart

1AKRO upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪3.16 B‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−3.62 EUR
Net income (FY)
‪−243.48 M‬ EUR
Revenue (FY)
0.00 EUR
Shares float
‪70.76 M‬
Beta (1Y)
0.95

Employees


Employees (FY)
63
Change (1Y)
+7 +12.50%
Revenue / Employee (1Y)
0.00 EUR
Net income / Employee (1Y)
‪−3.86 M‬ EUR

About Akero Therapeutics, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Andrew Cheng
Website
akerotx.com
Headquarters
South San Francisco
Founded
2017
FIGI
BBG01TNW8PW0
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

1AKRO news



Ideas



See all ideas 

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Check out other big names from the same industry as 1AKRO.

Frequently Asked Questions


The current price of 1AKRO is 38.80 EUR — it has decreased by −1.45% in the past 24 hours. Watch AKERO THERAPEUTICS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on MIL exchange AKERO THERAPEUTICS INC stocks are traded under the ticker 1AKRO.
1AKRO stock has risen by 9.71% compared to the previous week, the month change is a 9.71% rise, over the last year AKERO THERAPEUTICS INC has showed a 7.66% increase.
We've gathered analysts' opinions on AKERO THERAPEUTICS INC future price: according to them, 1AKRO price has a max estimate of 95.86 EUR and a min estimate of 43.09 EUR. Watch 1AKRO chart and read a more detailed AKERO THERAPEUTICS INC stock forecast: see what analysts think of AKERO THERAPEUTICS INC and suggest that you do with its stocks.
1AKRO reached its all-time high on May 2, 2025 with the price of 40.12 EUR, and its all-time low was 36.04 EUR and was reached on Apr 25, 2025. View more price dynamics on 1AKRO chart.
See other stocks reaching their highest and lowest prices.
1AKRO stock is 1.91% volatile and has beta coefficient of 0.95. Track AKERO THERAPEUTICS INC stock price on the chart and check out the list of the most volatile stocks — is AKERO THERAPEUTICS INC there?
Today AKERO THERAPEUTICS INC has the market capitalization of ‪3.15 B‬, it has increased by 8.14% over the last week.
Yes, you can track AKERO THERAPEUTICS INC financials in yearly and quarterly reports right on TradingView.
AKERO THERAPEUTICS INC is going to release the next earnings report on May 20, 2025. Keep track of upcoming events with our Earnings Calendar.
1AKRO earnings for the last quarter are −0.96 EUR per share, whereas the estimation was −1.12 EUR resulting in a 14.75% surprise. The estimated earnings for the next quarter are −0.89 EUR per share. See more details about AKERO THERAPEUTICS INC earnings.
AKERO THERAPEUTICS INC revenue for the last quarter amounts to 0.00 EUR, matching the estimated figure, and no changes in revenue are expected for the next quarter.
1AKRO net income for the last quarter is ‪−67.64 M‬ EUR, while the quarter before that showed ‪−65.30 M‬ EUR of net income which accounts for −3.59% change. Track more AKERO THERAPEUTICS INC financial stats to get the full picture.
No, 1AKRO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 7, 2025, the company has 63 employees. See our rating of the largest employees — is AKERO THERAPEUTICS INC on this list?
Like other stocks, 1AKRO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AKERO THERAPEUTICS INC stock right from TradingView charts — choose your broker and connect to your account.